Accelerated Access Review

In October 2016, the government’s Office for Life Sciences published the final report of the Accelerated Access Review.

The review was first announced in 2014. Its purpose was to look at improving access to innovative medicines and technologies across the NHS so that patients could benefit from new discoveries as quickly as possible.

Our position

We supported the review because its intentions closely aligned with our mission to improve health. 

The recommendations set out in the review mark one of the first steps towards making sure that promising drugs, devices, diagnostics and digital products are adopted quickly across the NHS. This means that medical research, including Wellcome-funded projects, could reach patients and transform lives more quickly. 

What we're doing

As part of our support for the review, we commissioned PricewaterhouseCoopers’ strategy consultancy, Strategy&, to investigate international pricing and reimbursement schemes, and how they may apply to the UK.

We also commissioned RAND Europe to assess how the take-up of innovations could be better supported across the NHS.

More information